Antisense approach to inflammatory bowel disease: prospects and challenges

Area of Science:

• Gastroenterology
• Molecular Biology
• Pharmacology

Background:

• Anti-tumour necrosis factor therapies are limited for Crohn's disease (CD) and ulcerative colitis (UC).
• New therapeutic targets and approaches are needed for inflammatory bowel diseases (IBDs).
• Antisense oligonucleotide (ASO) technology is emerging as a potential therapeutic strategy for IBDs.

Purpose of the Study:

• To review the rationale and clinical data for three antisense oligonucleotides (ASOs) in IBD treatment.
• To discuss the challenges and potential of ASO therapy in managing inflammatory bowel diseases.

Main Methods:

• Review of pre-clinical studies and clinical trial data for three specific ASOs: alicaforsen, DIMS0150, and mongersen.
• Analysis of ASO targets including intercellular adhesion molecule-1, nuclear factor (NF) κB-p65, and Smad7.

Main Results:

• Alicaforsen showed benefit as an enema for UC but not systemic for CD.
• DIMS0150 (targeting NF-κB-p65) shows promise in ongoing clinical trials.
• Mongersen (targeting Smad7) was safe and effective in inducing clinical remission in CD patients.

Conclusions:

• ASO therapy represents a novel approach for IBD management with varying efficacy depending on the agent and administration route.
• Further investigation and clinical trials are warranted to fully establish the role of ASOs in treating IBDs.
• Challenges in ASO delivery and application in IBD require continued research and development.